| Ytd | -31.88% | |
| 1y | 37.34% |
| Open | 67.78 | Prev Close | 67.87 | Low | 66.91 | High | 68.53 | Mkt Cap | 3.32B |
| Vol | 1.28M | Avg Vol | 1.24M | EPS | -4.31 | P/E | N/A | Forward P/E | -849.25 |
| Beta | 0.11 | Short Ratio | 14.14 | Inst. Own | 110.10% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-11 | 50-d Avg | 86.22 | 200-d Avg | 103.82 | 1yr Est | 156.91 |
CELC News
Rapid oral presentation of additional sub-group analyses from the VIKTORIA-1 PIK3CA mutant-type coho
Mr. Gryska brings decades of strategic and financial leadership experience to Celcuity's Board Mr. G
Celcuity, Inc. (NASDAQ: CELC - Get Free Report)'s share price gapped up prior to trading on Wednesda
This is a breast cancer treatment, Revtorpyk. It was approved by the FDA in July.
Needham analyst Gil Blum maintains Celcuity (NASDAQ:CELC) with a Buy and lowers the price target
Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targ
REVTORPYK is indicated for patients with HR+/HER2- advanced breast cancer without a PIK3CA mutation
JP Morgan analyst Anupam Rama initiates coverage on Celcuity (NASDAQ:CELC) with a Overweight rati
This whale alert can help traders discover the next big trading opportunities. Whales are entities w
Celcuity Inc. (CELC) Presents at Citigroup's Biopharma Back to School Summit 2026 Prepared Remarks T
MINNEAPOLIS, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology compan
Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targ
MINNEAPOLIS, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company
Brandywine Managers LLC acquired a new stake in shares of Celcuity, Inc. (NASDAQ: CELC) in the secon
Guggenheim analyst Brad Canino maintains Celcuity (NASDAQ:CELC) with a Buy and raises the price t
Citizens analyst Silvan Turkcan reiterates Celcuity (NASDAQ:CELC) with a Market Outperform and ma
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Celcuity (NASDAQ:CELC) with a B
Celcuity Inc. remains a Buy as the REVTORPYK/gedatolisib FDA approval and rapid NCCN Category 1 incl
Celcuity Inc (NASDAQ:CELC) reported a narrower-than-expected loss for the second quarter on Thursday
Celcuity Inc (NASDAQ:CELC) reported better-than-expected Q2 losses of $1.07 per share. Analysts are
Stifel analyst Stephen Willey maintains Celcuity (NASDAQ:CELC) with a Buy and lowers the price ta
Needham analyst Gil Blum maintains Celcuity (NASDAQ:CELC) with a Buy and lowers the price target
Celcuity Inc. (CELC) Q2 2026 Earnings Call Transcript
Celcuity NASDAQ: CELC said it remains on track to begin commercial shipments of REVTORPYK, its gedat
On Thursday, Celcuity (NASDAQ:CELC) discussed second-quarter financial results during its earnings c
Celcuity (NASDAQ:CELC) reported quarterly losses of $(1.07) per share which beat the analyst consens
MINNEAPOLIS, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company
California State Teachers Retirement System lifted its holdings in Celcuity, Inc. (NASDAQ: CELC) by
NEW YORK, Aug. 6, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
MINNEAPOLIS, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a commercial-stage biot
NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered L
The law firm of [url="]Kirby McInerney LLP[/url] reminds investors of its investigation on behalf of
Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targ
Gainers China Pharma Holding (AMEX:CPHI) shares moved upwards by 67.6% to $1.03 during Wednesday
Citizens analyst Silvan Turkcan maintains Celcuity (NASDAQ:CELC) with a Market Outperform and rai
Top Wall Street analysts changed outlook on top names. See all changes, including upgrades/downgrade
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Celcuity (NASDAQ:CELC) with a Bu
Celcuity Inc. (NASDAQ:CELC) ("Celcuity" or the "Company"), a clinical-stage biotechn
Craig-Hallum analyst Alexander Nowak maintains Celcuity (NASDAQ:CELC) with a Buy and lowers the p
Wells Fargo analyst Eva Fortea Verdejo maintains Celcuity (NASDAQ:CELC) with a Overweight and low
Top Wall Street analysts changed outlook on top names. For all rating changes, upgrades and downgrad
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Celcuity (NASDAQ:CELC) with a Bu
Celcuity Inc. (NASDAQ:CELC) ("Celcuity" or the "Company"), a clinical-stage biotechn
Celcuity reported Phase 3 data showing gedatolisib improved progression-free survival in PIK3CA-muta
Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on the development of ta
Global Business Travel Group Inc (GBTG), a NYSE-listed company, saw its stock rise 57% on Monday af
Wall Street analysts changed outlook on top names, including PRU, ARE, TRGP, VITL, and GOOGL. See an